A shallow pullback in CNC should be viewed as a buying opportunity.
I expect Allergan or another player to bid for SGYP soon.
Watch these names as stability returns to the sector.
Overall market and industry action could determine EW's next course.
The biotech juggernaut still has a lot going for it, especially at these levels.
The drug maker is a compelling buy and has 50% upside potential over the next 18 to 24 months.
I still like and own these small-caps.
I say this to those who are angry.
The charts are showing a long-term price target of $76.
Any turn in the fundamentals or sentiment easily can send these shares trading much higher from here.

Columnist Conversations

View Chart »  View in New Window » The S&P futures has held on top of a key symmetrical pr...
we are out of AAPL here as this one looks suspect. we'll cut this one here as the price action, technica...
Occidental is trading at new July lows this morning.  The stock is off just shy of 1.5% as the current pu...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.